Literature DB >> 33663022

Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers.

Michelle M Mielke1,2, Scott A Przybelski1, Timothy G Lesnick1, Silke Kern3, Henrik Zetterberg3,4,5,6, Kaj Blennow3,4, David S Knopman2, Jonathan Graff-Radford2, Ronald C Petersen1,2, Clifford R Jack7, Prashanthi Vemuri7.   

Abstract

INTRODUCTION: We determined whether cerebrospinal fluid (CSF) neurofilament light (NfL), neurogranin (Ng), and total-tau (t-tau) differentially mapped to magnetic resonance imaging (MRI) measures of cortical thickness, microstructural integrity (corpus callosum and cingulum fractional anisotropy [FA]), and white matter hyperintensities (WMH).
METHODS: Analyses included 536 non-demented Mayo Clinic Study of Aging participants with CSF NfL, Ng, t-tau, amyloid beta (Aβ)42 and longitudinal MRI scans. Linear mixed models assessed longitudinal associations between CSF markers and MRI changes.
RESULTS: Higher CSF NfL was associated with decreasing microstructural integrity and WMH. Higher t-tau was associated with decreasing temporal lobe and Alzheimer's disease (AD) meta region of interest (ROI) cortical thickness. There was no association between Ng and any MRI measure. CSF Aβ42 interacted with Ng for declines in temporal lobe and AD meta ROI cortical thickness and cingulum FA. DISCUSSION: CSF NfL predicts changes in white matter integrity, t-tau reflects non-specific changes in cortical thickness, and Ng reflects AD-specific synaptic and neuronal degeneration.
© 2020 the Alzheimer's Association.

Entities:  

Keywords:  Alzheimer's; amyloid; cerebrospinal fluid; cohort study; cortical thickness; magnetic resonance imaging; neurodegeneration; neurofilament light chain; neurogranin; total tau; white matter integrity

Mesh:

Substances:

Year:  2021        PMID: 33663022      PMCID: PMC8119371          DOI: 10.1002/alz.12239

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   16.655


  37 in total

1.  Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease.

Authors:  P Giannakopoulos; F R Herrmann; T Bussière; C Bouras; E Kövari; D P Perl; J H Morrison; G Gold; P R Hof
Journal:  Neurology       Date:  2003-05-13       Impact factor: 9.910

2.  Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca
Journal:  Int J Epidemiol       Date:  2012-11-18       Impact factor: 7.196

3.  Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.

Authors:  Rawan Tarawneh; Gina D'Angelo; Dan Crimmins; Elizabeth Herries; Terry Griest; Anne M Fagan; Gregory J Zipfel; Jack H Ladenson; John C Morris; David M Holtzman
Journal:  JAMA Neurol       Date:  2016-05-01       Impact factor: 18.302

4.  Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.

Authors:  Silke Kern; Jeremy A Syrjanen; Kaj Blennow; Henrik Zetterberg; Ingmar Skoog; Margda Waern; Clinton E Hagen; Argonde C van Harten; David S Knopman; Clifford R Jack; Ronald C Petersen; Michelle M Mielke
Journal:  JAMA Neurol       Date:  2019-02-01       Impact factor: 18.302

5.  White matter hyperintensities: relationship to amyloid and tau burden.

Authors:  Jonathan Graff-Radford; Eider M Arenaza-Urquijo; David S Knopman; Christopher G Schwarz; Robert D Brown; Alejandro A Rabinstein; Jeffrey L Gunter; Matthew L Senjem; Scott A Przybelski; Timothy Lesnick; Chadwick Ward; Michelle M Mielke; Val J Lowe; Ronald C Petersen; Walter K Kremers; Kejal Kantarci; Clifford R Jack; Prashanthi Vemuri
Journal:  Brain       Date:  2019-08-01       Impact factor: 13.501

6.  The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics.

Authors:  Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; V Shane Pankratz; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Ronald C Petersen; Walter A Rocca
Journal:  Neuroepidemiology       Date:  2008-02-07       Impact factor: 3.282

7.  Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.

Authors:  Niklas Mattsson; Philip S Insel; Sebastian Palmqvist; Erik Portelius; Henrik Zetterberg; Michael Weiner; Kaj Blennow; Oskar Hansson
Journal:  EMBO Mol Med       Date:  2016-10-04       Impact factor: 12.137

Review 8.  Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.

Authors:  Oskar Hansson; Sylvain Lehmann; Markus Otto; Henrik Zetterberg; Piotr Lewczuk
Journal:  Alzheimers Res Ther       Date:  2019-04-22       Impact factor: 6.982

9.  CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease.

Authors:  Shorena Janelidze; Henrik Zetterberg; Niklas Mattsson; Sebastian Palmqvist; Hugo Vanderstichele; Olof Lindberg; Danielle van Westen; Erik Stomrud; Lennart Minthon; Kaj Blennow; Oskar Hansson
Journal:  Ann Clin Transl Neurol       Date:  2016-01-01       Impact factor: 4.511

10.  A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.

Authors:  Lorenzo Gaetani; Kina Höglund; Lucilla Parnetti; Fani Pujol-Calderon; Bruno Becker; Paolo Eusebi; Paola Sarchielli; Paolo Calabresi; Massimiliano Di Filippo; Henrik Zetterberg; Kaj Blennow
Journal:  Alzheimers Res Ther       Date:  2018-01-23       Impact factor: 6.982

View more
  4 in total

Review 1.  Biofluid Biomarkers of Alzheimer's Disease: Progress, Problems, and Perspectives.

Authors:  Shan Huang; Yan-Jiang Wang; Junhong Guo
Journal:  Neurosci Bull       Date:  2022-03-19       Impact factor: 5.271

2.  A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and non-converter Alzheimer's disease subjects with consideration for their amyloid beta status.

Authors:  Ulyana Morar; Walter Izquierdo; Harold Martin; Parisa Forouzannezhad; Elaheh Zarafshan; Elona Unger; Zoran Bursac; Mercedes Cabrerizo; Armando Barreto; David E Vaillancourt; Steven T DeKosky; David Loewenstein; Ranjan Duara; Malek Adjouadi
Journal:  Alzheimers Dement (Amst)       Date:  2022-02-23

Review 3.  Tauopathies: new perspectives and challenges.

Authors:  Yi Zhang; Kai-Min Wu; Liu Yang; Qiang Dong; Jin-Tai Yu
Journal:  Mol Neurodegener       Date:  2022-04-07       Impact factor: 14.195

4.  Sleepiness in Cognitively Unimpaired Older Adults Is Associated With CSF Biomarkers of Inflammation and Axonal Integrity.

Authors:  Diego Z Carvalho; Erik K St Louis; Scott A Przybelski; Timothy I Morgenthaler; Mary M Machulda; Bradley F Boeve; Ronald C Petersen; Clifford R Jack; Jonathan Graff-Radford; Prashanthi Vemuri; Michelle M Mielke
Journal:  Front Aging Neurosci       Date:  2022-07-11       Impact factor: 5.702

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.